目的 探讨卵巢癌患者围手术期血清胰岛素样生长因子-2(IGF-2)和胰岛素样生长因子结合蛋白-3(IGFBP-3)的变化及其临床意义.方法 采用酶联吸附免疫法(ELISA)测定40例健康对照组及82例卵巢癌患者手术前后血清IGF-2和IGFBP-3的水平,观察健康对照组与卵巢癌患者手术前后血清IGF-2和IGFBP-3的水平变化,分析卵巢癌病人血清IGF-2和IGFBP-3水平与临床特征的关系.结果 卵巢癌手术前病人血清IGF-2及IGFBP-3水平明高于正常对照组[(101.5±22.2)ng/ml,(49.3±15.6)ng/ml vs (69.6±17.7)ng/ml,(23.9±11.3)ng/ml,t＝3.74,2.85,P＜0.05];卵巢癌病人有淋巴结转移者血清IGF-2水平[(109.4±20.0)ng/ml]高于无淋巴结转移者[(89.9±16.6)ng/ml](t′＝4.10,P＜0.05),而IGFBP-3水平[(39.8±11.1)ng/ml]低于无淋巴结转移者[(55.8±19.2)ng/ml](t′＝4.49,P＜0.05);肿瘤临床TNM分期中III～IV期者血清IGF-2水平[(107.5±24.0)ng/ml]高于I～II期者[(91.6±17.7)ng/ml](t＝2.83,P＜0.05),而IGFBP-3水平[(41.7±16.9)ng/ml]低于I～II期者[(56.9±19.1)ng/ml](t＝2.37,P＜0.05),根治性手术组病人术后IGF-2及IGFBP-3水平明显低于术前[(103.4±27.2)ng/ml,(50.2±16.6)ng/ml vs (86.6±12.3)ng/ml,(41.1±17.1)ng/ml,t＝2.48,3.32,P＜0.05],姑息性手术组病人术前术后血清IGF-2及IGFBP-3水平无明显变化(P＞0.05).根治性手术组病人术后血清IGF-2及IGFBP-3水平低于姑息性手术组术后[(86.6±12.3)ng/ml,(41.1±17.1)ng/ml vs (103.2±26.0)ng/ml,(45.3±14.9)ng/ml,t′＝3.46,t＝2.67,P＜0.05].结论 卵巢癌患者血清IGF-2和IGFBP-3的水平与肿瘤的浸润转移、临床分期及根治性手术有关,动态检测卵巢癌患者血清IGF-2和IGFBP-3的变化,有助于估计患者的预后。